The DOI matches its Crossref record; 452 of the 460 references it cites were found in a registry or an index.
CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022
Open accessAbstract
This guideline provides recommendations for clinicians providing pain care, including those prescribing opioids, for outpatients aged ≥18 years.It updates the CDC Guideline for Prescribing Opioids for Chronic Pain -United States, 2016 (MMWR Recomm Rep 2016;65[No.RR-1]:1-49) and includes recommendations for managing acute (duration of <1 month), subacute (duration of 1-3 months), and chronic (duration of >3 months) pain.The recommendations do not apply to pain related to sickle cell disease or cancer or to patients receiving palliative or end-of-life care.The guideline addresses the following four areas: 1) determining whether or not to initiate opioids for pain, 2) selecting opioids and determining opioid dosages, 3) deciding duration of initial opioid prescription and conducting follow-up, and 4) assessing risk and addressing potential harms of opioid use.CDC developed the guideline using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) framework.Recommendations are based on systematic reviews of the scientific evidence and reflect considerations of benefits and harms, patient and clinician values and preferences, and resource allocation.CDC obtained input from the Board of Scientific Counselors of the National Center for Injury Prevention and Control (a federally chartered advisory committee), the public, and peer reviewers.CDC recommends that persons with pain receive appropriate pain treatment, with careful consideration of the benefits and risks of all treatment options in the context of the patient's circumstances.Recommendations should not be applied as inflexible standards of care across patient populations.This clinical practice guideline is intended to improve communication between clinicians and patients about the benefits and risks of pain treatments, including opioid therapy; improve the effectiveness and safety of pain treatment; mitigate pain; improve function and quality of life for patients with pain; and reduce risks associated with opioid pain therapy, including opioid use disorder, overdose, and death.MMWR / November 4, 2022 / Vol.71 / No. 3 US Department of Health and Human Services/Centers for Disease Control and Prevention pain outcomes, psychological distress, overdose, and suicidal ideation and behavior (66-71). RationaleSince release of the 2016 CDC Opioid Prescribing Guideline, new evidence has emerged on the benefits and risks of prescription opioids for both acute and chronic pain, comparisons with nonopioid pain treatments, dosing strategies, opioid dose-dependent effects, risk mitigation strategies, and opioid tapering and discontinuation (7)(8)(9)(10)(11).This evidence includes studies on misapplication of the 2016 CDC Opioid Prescribing Guideline (66), benefits and risks of different tapering strategies and rapid tapering associated with patient harm (68,71-73), challenges in patient access to opioids (6), patient abandonment and abrupt discontinuation of opioids (71), a seminal randomized clinical trial comparing prescription opioids to nonopioid medications on long-term pain outcomes (74), the association of characteristics of initial opioid prescriptions with subsequent likelihood for long-term opioid use (75,76), and the small proportion of opioids used by patients compared with the amount prescribed to them for postoperative pain (77-79).Opioid medications remain a common treatment for pain despite declines in the number of opioid prescriptions after 2012 (58).During 2015-2018, approximately 6% of U.S. adults reported use of one or more prescription opioids during the past 30 days (80), and in 2020, approximately 143 million opioid prescriptions were dispensed from pharmacies in the United States (81).Rates of opioid prescribing continue to vary across states, medical specialties, patient demographics, and pain conditions in ways that cannot be explained by the underlying health status of the population, and often are discordant with the 2016 CDC Opioid Prescribing Guideline recommendations (25,77,(82)(83)(84).The prevalence of prescription opioid misuse and prescription opioid use disorder also has declined in recent years.In 2019, among persons aged ≥12 years in the United States, 9.7 million reported misuse of prescription opioids during the past year (a decrease from 12.5 million in 2015), and 1.4 million met criteria for a past-year prescription opioid use disorder (a decrease from 2.0 million in 2015) (85).However, in 2020, prescription opioids remained the most commonly misused prescription drug in the United States (51).Also in 2020, among those reporting misuse during the past year, 64.6% reported the main reason for their most recent misuse was to "relieve physical pain" compared with 11.3% to "feel good or get high" and 2.3% "because I am hooked or have to have it" (51).Taken together, these factors underscore the need for an updated clinical practice guideline on appropriate opioid prescribing for pain and pain management.MMWR /
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The median duration of NRT use is ≤ 2 weeks despite package instructions [67].”
From A National Dental Practice-Based Research Network phase II, cluster-randomized clinical trial assessing nicotine replacement therapy sampling in dental settings: study protocol for the Free Samples for Health (FreSH) study (2024) · cites this paper as [67]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
(1992) · PubMed · Cited by 33,716
The MOS 36-ltem Short-Form Health Survey (SF-36): I. Conceptual Framework and Item Selection
Ware, J. E., & Sherbourne, C. D. (1992) · Medical Care · doi:10.1097/00005650-199206000-00002 · Cited by 30,033
GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
Guyatt, G. H., Oxman, A. D., Vist, G. E., Kunz, R., Falck-Ytter, Y., Alonso-Coello, P., & Schünemann, H. J. (2008) · BMJ · doi:10.1136/bmj.39489.470347.ad · Cited by 23,305
The National Comprehensive Cancer Network: Present and future directions
McGivney, W. T. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980515)82:10+<2057::aid-cncr14>3.0.co;2-a · Cited by 16,766
GRADE guidelines: 3. Rating the quality of evidence
Balshem, H., Helfand, M., Schünemann, H. J., Oxman, A. D., Kunz, R., Brozek, J., Vist, G. E., Falck-Ytter, Y., Meerpohl, J., & Norris, S. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.07.015 · Cited by 8,285
Bush, K. (1998) · Archives of Internal Medicine · doi:10.1001/archinte.158.16.1789 · Cited by 6,196
Fairbank, J. C. T., & Pynsent, P. B. (2000) · Spine · doi:10.1097/00007632-200011150-00017 · Cited by 5,851
Pain assessment: global use of the Brief Pain Inventory.
Cs, C., & Km, R. (1994) · PubMed · Cited by 5,421
Kroenke, K., Spitzer, R. L., Williams, J. B. W., & Löwe, B. (2010) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2010.03.006 · Cited by 4,057
Research works printed but not linked: 28
- Chou R, Wagner J, Ahmed A, Treatments for acute pain: a systematic review. Comparative effectiveness review no. 240. Rockville, MD: Agency for Healthcare Research and Quality; 2020.
- Laffer A, Murphy R, Winegarden W, et al. An economic analysis of the costs and benefits associated with regular urine drug testing for chronic pain patients in the United States. Nashville, TN: Laffer Associates; 2011. https://www.researchgate.net/publication/268175852_An_Economic_Analysis_of_the_Costs_and_Benefits_Associated_with_Regular_Urine_Drug_Testing_for_Chronic_Pain_Patients_in_the_United_States_Laffer_Associates_An_Economic_Analysis_of_the_Costs_and_Benefit
- Institute of Medicine. Relieving pain in America: a blueprint for transforming prevention, care, education, and research. Washington, DC: National Academies Press; 2011.
- Banerjee S, Argáez C. Multidisciplinary treatment programs for patients with acute or subacute pain: a review of clinical effectiveness, cost-effectiveness, and guidelines [Internet]. Ottawa, ON: Canadian Agency for Drugs and Technologies in Health; 2019 May 7. https://www.ncbi.nlm.nih.gov/books/NBK546002/
- Chou R, Hartung D, Turner J, Opioid treatments for chronic pain. Comparative effectiveness review no. 229. Rockville, MD: Agency for Healthcare Research and Quality; 2020. · DOI
- McDonagh M, Selph S, Buckley D, Nonopioid pharmacologic treatments for chronic pain. Comparative effectiveness review no. 228. Rockville, MD: Agency for Healthcare Research and Quality; 2020. · DOI
- Skelly A, Chou R, Dettori J, Noninvasive nonpharmacological treatment for chronic pain: a systematic review update. Comparative effectiveness review no. 227. Rockville, MD: Agency for Healthcare Research and Quality; 2020. · DOI · Paper page
- Chou R, Wagner J, Ahmed A, Treatments for acute pain: a systematic review. Comparative effectiveness review no. 240. Rockville, MD: Agency for Healthcare Research and Quality; 2020.
- Halker Singh R, VanderPluym J, Morrow A, Acute treatments for episodic migraine. Comparative effectiveness review no. 239. Rockville, MD: Agency for Healthcare Research and Quality; 2020. · DOI
- Heyward, 2018, Coverage of nonpharmacologic treatments for low back pain among US public and private insurers., JAMA Netw Open, 1, e183044, 10.1001/jamanetworkopen.2018.3044 · DOI · Paper page
- Chou R, Deyo R, Devine B, The effectiveness and risks of long-term opioid treatment of chronic pain. Evidence report/technology assessment no. 218. AHRQ publication no. 14–E005-EF. Rockville, MD: Agency for Healthcare Research and Quality; 2014. · DOI · Paper page
- Dowell, 2016, CDC guideline for prescribing opioids for chronic pain—United States, 2016., MMWR Recomm Rep, 65, 1, 10.15585/mmwr.rr6501e1 · DOI · Paper page
- Mark, 2019, Opioid medication discontinuation and risk of adverse opioid-related health care events., J Subst Abuse Treat, 103, 58, 10.1016/j.jsat.2019.05.001 · DOI · Paper page
- James, 2019, Mortality after discontinuation of primary care-based chronic opioid therapy for pain: a retrospective cohort study., J Gen Intern Med, 34, 2749, 10.1007/s11606-019-05301-2 · DOI
- Krebs, 2018, Effect of opioid vs nonopioid medications on pain-related function in patients with chronic back pain or hip or knee osteoarthritis pain: The SPACE randomized clinical trial., JAMA, 319, 872, 10.1001/jama.2018.0899 · DOI · Paper page
- National Academies of Sciences, Engineering, and Medicine. Framing opioid prescribing guidelines for acute pain: developing the evidence. Washington, DC: National Academies Press; 2019.
- Committee on Approaching Death: Addressing Key End of Life Issues: Institute of Medicine. Dying in America: improving quality and honoring individual preferences near the end of life. Washington, DC: National Academies Press; 2015.
- Banerjee S, McCormack S. Medical cannabis for the treatment of chronic pain: a review of clinical effectiveness and guidelines. Ottawa, ON: Canadian Agency for Drugs and Technologies in Health; 2019.
- Ostelo, 2008, Interpreting change scores for pain and functional status in low back pain: towards international consensus regarding minimal important change., Spine, 33, 90, 10.1097/BRS.0b013e31815e3a10 · DOI · Paper page
- Dunn, 2010, Opioid prescriptions for chronic pain and overdose: a cohort study., Ann Intern Med, 152, 85, 10.7326/0003-4819-152-2-201001190-00006 · DOI · Paper page
- Agnoli, 2021, Association of dose tapering with overdose or mental health crisis among patients prescribed long-term opioids., JAMA, 326, 411, 10.1001/jama.2021.11013 · DOI · Paper page
- Hallvik, 2022, Patient outcomes after opioid dose reduction among patients with chronic opioid therapy., Pain, 163, 83, 10.1097/j.pain.0000000000002298 · DOI
- Sullivan, 2017, Prescription opioid taper support for outpatients with chronic pain: a randomized controlled trial., J Pain, 18, 308, 10.1016/j.jpain.2016.11.003 · DOI
- Coffin, 2016, Nonrandomized intervention study of naloxone coprescription for primary care patients receiving long-term opioid therapy for pain., Ann Intern Med, 165, 245, 10.7326/M15-2771 · DOI · Paper page
- Lin, 2017, Physician attitudes and experiences with Maryland’s prescription drug monitoring program (PDMP)., Addiction, 112, 311, 10.1111/add.13620 · DOI
- American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington, VA: American Psychiatric Publishing; 2013. · DOI · Paper page
- Vowles, 2015, Rates of opioid misuse, abuse, and addiction in chronic pain: a systematic review and data synthesis., Pain, 156, 569, 10.1097/01.j.pain.0000460357.01998.f1 · DOI · Paper page
- National Academies of Sciences, Engineering, and Medicine. Pain management and the opioid epidemic: balancing societal and individual benefits and risks of prescription opioid use. Washington, DC: National Academies Press; 2017.
Cited by
Chronic Pain Among Adults — United States, 2019–2021
Rikard, S. M., Strahan, A. E., Schmit, K. M., & Guy, G. P. (2023) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7215a1 · Cited by 588
Treatment for Opioid Use Disorder: Population Estimates — United States, 2022
Dowell, D., Brown, S., Gyawali, S., Hoenig, J., Ko, J., Mikosz, C., Ussery, E., Baldwin, G., Jones, C. M., Olsen, Y., et al. (2024) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7325a1 · Cited by 261
“††† Several factors limit access to medications for OUD despite strong recommendations for their use ( 4 , 5 ).”
BackgroundMethodSelf-citationNelson, G., Fotopoulou, C., Taylor, J., Glaser, G., Bakkum-Gamez, J., Meyer, L. A., Stone, R., Mena, G., Elias, K. M., Altman, A. D., et al. (2023) · Gynecologic Oncology · doi:10.1016/j.ygyno.2023.04.009 · Cited by 206
Jones, C. M. P., Day, R. O., Koes, B. W., Latimer, J., Maher, C. G., McLachlan, A. J., Billot, L., Shan, S., Lin, C.-W. C., McLachlan, H., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00404-x · Cited by 164
Self-citationPrescribing Opioids for Pain — The New CDC Clinical Practice Guideline
Dowell, D., Ragan, K. R., Jones, C. M., Baldwin, G. T., & Chou, R. (2022) · New England Journal of Medicine · doi:10.1056/nejmp2211040 · Cited by 136
Self-citation
Metadata
- Authors
- Dowell, D., Ragan, K. R., Jones, C. M., Baldwin, G. T., & Chou, R.
- Affiliations
- National Center for Injury Prevention and Control (US)
- Centers for Disease Control and Prevention (US)
- Oregon Health & Science University (US)
- Corresponding author
- Dowell, Deborah
- Venue
- MMWR. Recommendations and Reports
- Published
- 2022-11-04
- Volume
- 71
- Issue
- 3
- Pages
- 1-95
- ISSN
- 1057-5987 (ISSN-L)
- 1545-8601
- PMC
- PMC9639433
- OpenAlex
- W4308369850
- Cited by
- 1,886
- References
- 460
- Citations by year
- 2026: 504 · 2025: 568 · 2024: 475 · 2023: 324 · 2022: 13
- FWCI
- 304.62
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- public-domain
- Locations
- MMWR Recommendations and Reports (publishedVersion, public-domain)
- PubMed Central (publishedVersion, public-domain)
- PubMed (publishedVersion)
- Funders
- Centers for Disease Control and Prevention
- National Center for Injury Prevention and Control
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Opioid Use
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Anesthesia and Pain Management
- Keywords
- opioid prescribing, chronic pain, acute pain, subacute pain, opioid use disorder, opioid overdose, opioid-related harms, opioid tapering, opioid dose titration, opioid risk assessment, non-opioid analgesics, pain management, opioid-related deaths
- MeSH terms
- Adolescent, Adult, Analgesics, Opioid, Centers for Disease Control and Prevention, U.S., Humans, Opioid-Related Disorders, Quality of Life, United States, Chronic Pain
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022. https://app.cochat.ai/papers/10.15585/mmwr.rr7103a1
- The paper
- Dowell, D., Ragan, K. R., Jones, C. M., Baldwin, G. T., & Chou, R. (2022). CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022. MMWR. Recommendations and Reports. https://doi.org/10.15585/mmwr.rr7103a1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.